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Background: Hepatocellular carcinoma (HCC) has a high predilection for portal vein invasion, and the prognosis of
HCC with malignant portal vein invasion is extremely poor. The objective of this study was to investigate the
outcomes and the prognostic factor of recurrence in HCC patients with malignant portal vein invasion.
Methods: We retrospectively reviewed the clinicopathologic data and outcomes of 83 HCC patients with malignant
portal vein invasion and 1,056 patients without portal vein invasion who underwent liver resection.
Results: Increased serum alkaline phosphatase (ALP) levels, increased maximum tumor size, and intrahepatic
metastasis were predisposing factors for malignant portal vein invasion by multivariate analysis. The median
disease-free survival and overall survival of HCC patients with malignant portal vein invasion was 4.5 months and 25
months, respectively. The 1-year, 2-year, and 3-year disease-free survival rates were 30.6%, 26.1%, and 21.2%,
respectively, and the overall survival rates for HCC patients with malignant portal vein invasion were 68.6%, 54.2%,
and 41.6%, respectively. The initial detection site was the lung in HCC patients with portal vein invasion and the
liver in HCC patients without portal vein invasion. C-reactive protein (CRP) was a significant independent predictor
of tumor recurrence in HCC with malignant portal vein invasion after surgery.
Conclusions: Increased ALP levels, increased maximum tumor size, and intrahepatic metastasis were independent
predictors of malignant portal vein invasion in HCC. CRP level was closely associated with the predisposing factor of
tumor recurrence in HCC patients with malignant portal vein invasion after a surgical resection, and lung metastasis
was common.
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Tumor recurrenceBackground
Hepatocellular carcinoma (HCC) is a leading cause of
cancer death, and its incidence is particularly high in
Asian countries, including Korea. Chronic hepatitis B is
endemic in Korea, representing the most important risk
factor and constituting approximately 70% of all HCC
cases [1].
The prognosis of HCC is very poor as a result of
intrahepatic metastasis and recurrence, which are closely* Correspondence: jw.joh@samsung.com
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reproduction in any medium, provided the orassociated with portal vein invasion [2,3]. HCC has a
tendency to invade the portal vein causing tumor throm-
bosis, which has been shown to be an adverse prognostic
factor for HCC [4]. The prognosis of HCC with portal
vein tumor invasion is extremely poor, with a median
survival of 2.7 to 4 months without intervention [5].
However, the characteristics of HCC with malignant
portal vein invasion are not well understood.
Although liver transplantation for HCC alters the na-
tural history of this disease, liver resection remains one
of the main treatment modalities that can provide a
good outcome [6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with portal vein invasion to patients without portal vein
invasion and analyzed the predisposing factors of tumor
recurrence in HCC patients with malignant portal vein
invasion who underwent liver resection.Methods
Patients
From January 2006 to June 2010, 1,139 patients who
were newly diagnosed with HCC underwent liver resec-
tion at Samsung Medical Center. The diagnoses of HCC
with malignant portal vein invasion were confirmed by a
histologic examination after surgery. We excluded pa-
tients who were younger (age <18 years), had patho-
logically proven mixed hepatocellular carcinoma and
cholangiocarcinoma, or who were lost to follow-up after
liver resection. The demographic, preoperative labora-
tory, and pathologic data of all patients were collected
from the electronic medical record (EMR) and retro-
spectively reviewed. The Child-Pugh classification sys-
tem was used to evaluate liver function.Surgery and pathology
Selection criteria for the liver resection procedure
depended on tumor location and extent, liver func-
tion, and future liver remnant volume. Child-Pugh
class C, severe co-morbidity, and distant metastasis
were considered contraindications for hepatectomy. A
standard operative technique for the hepatectomy was
used for these tumors. Depending on the part of liver
to be resected, adequate mobilization was performed.
Selective clamping of the portal vein and hepatic ar-
tery was performed when feasible; if not, intermittent
the Pringle maneuver was performed. The parenchy-
mal transection was performed using Cavitron Ultra-
sonic Surgical Aspirator (CUSA) under low central
venous pressure. A major hepatectomy was defined
as a resection of three or more Couinaud segments,
and minor hepatectomy was defined as resection of
less than three segments. R0 resection status was de-
fined as the presence of microscopic tumor >1 mm
from the resection margin.
Postoperative histological assessment and reporting in-
cluded the maximal tumor diameter, capsular formation,
capsular invasion, portal vein invasion, bile duct inva-
sion, microvascular invasion, serosal involvement, in-
trahepatic metastasis, multicentric occurrence of HCC,
cirrhosis, resection margin, and others. Histologic grade
of HCC was assessed according to the Edmonson-
Steiner grade system, and groups as well differentiated
(grade I), moderate differentiated (grade II), or poorly
differentiated (grades III, IV) [7].Surveillance after surgical resection
After surgery, the patients with HCC with pathologic
portal vein invasion were followed up every 2 to 3 months
in the postoperative period. A follow-up included physical
examination, serum alpha-fetoprotein (AFP), protein in-
duced by vitamin K antagonist (PIVKA)-II, liver function
test, and chest X-ray. An abdominal computed tomog-
raphy (CT) was performed every 3 months or when in-
trahepatic recurrence was suspected. Magnetic resonance
imaging (MRI) and/or positron emission tomography
(PET) scan were performed as CT could not show defini-
tively the evidence of recurrence. Detailed information on
patients who were identified to have peritoneal recurrence
was recorded. Patients with intrahepatic recurrence were
treated with radiofrequency ablation (RFA), transarterial
chemoembolization (TACE), or sorafenib according to
their liver function reserve and the pattern of recurrence.
The follow-up time was defined as the length of time from
surgery to last follow-up (December 1, 2011) or death.
None of the patients were lost to follow-up or died within
30 days after surgery, and 1,139 patients were included in
the survival analysis.
Statistical analysis
All data were analyzed using SPSS statistical software
(Ver 19.0; SPSS Inc., Chicago, IL, USA). Continuous var-
iables are presented as the median and range and were
compared by Mann–Whitney U test. Categorical vari-
ables were compared by Fisher’s exact test. A multivari-
ate analysis was performed to identify the risk factors of
the pathological portal vein invasion using logistic re-
gression analysis. The disease-free survival rates and
overall survival rates were calculated with the Kaplan-
Meier method and compared using the log-rank test.
Univariate and multivariate analyses were performed to
identify the risk factors of HCC recurrence in HCC with
pathologic portal vein invasion using Cox regression
model. A P value of <0.05 was considered statistically
significant.
Results
Demographics of HCC patients with portal vein invasion
The clinicopathologic features of HCC patients with ma-
lignant portal vein invasion and HCC patients without
malignant portal vein invasion are summarized in
Table 1. Of the 83 HCC patients (7.3%) with malignant
portal vein invasion, there were 71 men and 12 women,
with a median age of 49 years (range, 20–72 years).
There were 1,056 (92.7%) HCC patients without portal
vein invasion, and their median age was 54 years (range,
19–92 years). The age of HCC patients with malignant
portal vein invasion was lower than that of HCC patients
without portal vein invasion (P <0.001). Most cases of
HCC were caused by hepatitis B virus (HBV), and
Table 1 Characteristics of HCC patients with and without portal vein invasion
Variables HCC with PV invasion HCC without PV invasion P value
(n=83, 7.3%) (n=1056, 92.7%)
Gender 0.252
Male 71 (85.5%) 842 (79.7%)
Female 12 (14.5%) 214 (20.3%)
Age (years) 49 (20–72) 54 (19–82) <0.001
Etiology 0.447
HBV 63 (75.9%) 816 (77.6%)
HCV 4 (4.8%) 54 (5.1%)
Alcohol 4 (4.8%) 19 (1.8%)
Non-B, non-C 10 (12.0%) 142 (13.5%)
Others 2 (2.4%) 20 (1.9%)
Locoregional therapy 0.070
None 64 (77.1%) 907 (85.9%)
TACE 18 (21.7%) 127 (12.0%)
RFA 1 (1.2%) 13 (1.2%)
TACE and RFA 0 (0%) 9 (0.9%)
White blood cells (/uL) 5,730 (2,520–10,530) 5,460 (1,270–16,530) 0.103
Hemoglobin (g/dL) 14.3 (9.8–17.0) 14.2 (8.1–16.8) 0.360
Platelet counts (/uL) 174,000 (80,000–627,000) 160,000 (19,000–708,000) 0.125
INR 1.09 (0.93–1.32) 1.08 (0.84–1.59) 0.901
Albumin (g/dL) 4.1 (2.9–5.0) 4.1 (2.1–5.3) 0.423
Total bilirubin (mg/dL) 0.7 (0.2–3.5) 0.7 (0.2–4.3) 0.310
AST (U/L) 43 (23–283) 35 (14–353) <0.001
ALT (U/L) 44 (17–288) 35 (13–385) 0.002
ALP (U/L) 93 (38–233) 79 (32–562) <0.001
GGT (U/L) 105 (17–1,442) 49 (8–1,322) <0.001
Creatinine (mg/dL) 0.86 (0.44–1.27) 0.88 (0.42–5.87) 0.586
Estimated GFR (mL/min) 98.6 (72.2–149.2) 89.4 (5.7–189.0) 0.003
CRP (mg/dL) 0.27 (0.04–28.62) 0.13 (0.01–22.24) 0.048
AFP (ng/mL) 813.2 (1.8–200,000) 26.4 (1.0–2,121,720) <0.001
PIVKA-II (mAU/mL) 482.0 (12–1,200) 42.0 (2–2,000) <0.001
Operation <0.001
Anatomical 61 (73.5%) 540 (51.1%)
Non-anatomical 22 (26.5%) 516 (48.9%)
Hepatectomy <0.001
Major 50 (60.2%) 274 (25.9%)
Minor 33 (39.8%) 782 (74.1%)
Resection 0.035
R 0 77 (93.9%) 1029 (98.0%)
R 1 5 (6.1%) 21 (2.0%)
Margin (mm) 10 (1–53) 10 (1–80) 0.331
Maximum tumor size (mm) 6.0 (1.4–17.5) 3.3 (0.2–21.0) <0.001
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Table 1 Characteristics of HCC patients with and without portal vein invasion (Continued)
Grade 0.001
1 and 2 67 (80.7%) 976 (92.4%)
3 and 4 16 (19.3%) 80 (7.6%)
Cirrhosis 40 (48.2%) 468 (44.3%) 0.494
Capsule formation <0.001
None 33 (39.8%) 69 (6.6%)
Complete 35 (42.2%) 875 (83.2%)
Partial 15 (18.1%) 108 (10.3%)
Bile duct invasion 7 (8.4%) 24 (2.3%) 0.005
Serosa involvement 2 (2.4%) 12 (1.1%) 0.272
Intrahepatic metastasis 41 (49.4%) 112 (10.6%) <0.001
Multicentric occurrence 1 (1.2%) 57 (5.4%) 0.118
Hospitalization 9 (5–53) 9 (3–102) 0.932
Duration of Follow-up (months) 18 (5–68) 32 (3–82) <0.001
AFP, Alpha-fetoprotein; ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CRP, C-reactive protein; GFR, Estimated
glomerular filtration rate; GGT, Gamma-glutamyl transferase; HBV, Hepatitis B virus; HCV, Hepatitis C virus; INR, International normalized ratio; PIVKA-II, Protein
induced by vitamin K antagonist-II; PV, Portal vein; RFA, Radiofrequency ablation; TACE, Transarterial chemoembolization.
Table 2 Risk factors for portal vein invasion in HCC by
multivariate analysis
Variables Hazard ratio 95% confidence
interval
P value
ALP 1.017 1.005–1.030 0.007
Maximum tumor size 1.025 1.010–1.040 0.001
Intrahepatic metastasis 6.064 1.553–23.673 0.009
ALP, Alkaline phosphatase.
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ceive radiation in the preoperative period. There were
no differences in gender, cause, and type of locoregional
therapy between the two groups. As for laboratory data
before the operation, the HCC patients with malignant
portal vein invasion had higher serum aspartate amino-
transferase (AST), alanine aminotransferase (ALT), alka-
line phosphatase (ALP), gamma-glutamyl transferase
(GGT), estimated glomerular filtration rate (GFR), and
C-reactive protein (CRP) levels compared with HCC pa-
tients without portal vein invasion (P <0.05). However,
white blood cell (WBC) count, hemoglobin, platelet
count, INR, albumin, total bilirubin, direct bilirubin, and
creatinine were similar in both groups. The median of
AFP and PIVKA-II in HCC patients with malignant por-
tal vein invasion was 813.2 ng/mL (range, 1.8–200,000
ng/mL) and 482.0 mAU/mL (range, 12–1,200 mAU/mL),
respectively, but the median in HCC patients without por-
tal vein invasion was 26.4 ng/mL (range, 1.0–2,121,720
ng/mL) and 42.0 mAU/mL (range, 2–2,000 mAU/mL),
respectively (P <0.001 and P <0.001, respectively).
The surgery and pathologic results in HCC patients with
malignant portal vein invasion
The proportion of anatomical resection and major hepa-
tectomy in HCC patients with malignant portal vein in-
vasions was higher than that in HCC patients without
portal vein invasion (P <0.001 and P <0.001, respect-
ively). Postoperative mortality was not occurred in the
patients with malignant portal vein invasion. Patholo-
gically proven malignant portal vein invasion consisted
of segmental portal vein invasion (n=57) and left or right
main portal vein invasion (n=26). Left or right mainportal vein invasion was detected in the preoperative
radiology, but segmental portal vein invasion was not di-
agnosed in the preoperative radiology. The median
tumor size was 6 cm (range, 1.4–17.5 cm) in HCC with
malignant portal vein invasion and 3.3 cm (range, 0.2–
21.0 cm) in HCC without portal vein invasion (P<0.001).
The proportion of R1 resection in HCC patients with
malignant portal vein invasion was 6.1%, which was
higher than that in HCC patients without portal vein in-
vasion (P=0.035). None of the studied patients had
distant metastasis and there was no patient with R2 re-
section in this study. There were 16 cases (19.3%) of
grade 3 or 4 HCC with malignant portal vein invasion
and 80 (7.6%) cases of HCC without portal vein invasion.
The grade in HCC with malignant portal vein invasion
was poorer than that in HCC without portal vein inva-
sion (P=0.001). Bile duct invasion, intrahepatic metasta-
sis, and the absence of capsular formation were more
prevalent in HCC with portal vein invasion than in HCC
without portal vein invasion (P <0.05). However, no
significant difference was found in serosa involvement
and multicentric occurrence between the two groups.
The median hospitalization in both groups was 9 days
and the duration of follow-up in HCC patients with
Figure 1 (A) Disease-free survival rate and (B) overall survival rate in HCC patients according to portal vein invasion. The disease-free
survival curve and overall survival curve in HCC patients with malignant portal invasion were inferior to those in HCC patients without portal
vein invasion.
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Table 3 Initial detection site for recurrence after surgical
resection
Recurrence





Liver 18 (26.9%) 254 (62.0%) <0.001
Lung 34 (50.7%) 95 (23.2%) <0.001
Bone 7 (10.4%) 22 (5.4%) 0.161
Brain 0 (0%) 5 (1.2%) 0.364
Peritoneum 8 (11.9%) 34 (8.3%) 0.351
Table 5 Risk factors for tumor recurrence in HCC patients
with portal vein invasion by univariate analysis
Variables Hazard ratio 95% confidence
interval
P value
Gender - Female 0.657 0.313–1.376 0.265
Age 0.973 0.946–1.000 0.052
AFP 1.000 1.000–1.000 0.005
PIVKA-II 1.001 1.000–1.001 0.128
Locoregional therapy 1.495 0.848–2.634 0.165
White blood cells 0.961 0.835–1.107 0.582
Hemoglobin 1.010 0.853–1.195 0.909
Platelet counts 1.000 0.998–1.003 0.821
INR 6.056 0.254–144.219 0.266
Albumin 0.533 0.290–0.980 0.043
Total bilirubin 1.047 0.654–1.676 0.849
AST 1.005 0.999–1.011 0.103
ALT 1.002 0.996–1.008 0.565
ALP 1.002 0.995–1.008 0.643
Creatinine 0.427 0.091–2.004 0.281
Estimated GFR 1.015 0.997–1.033 0.102
GGT 1.000 0.998–1.001 0.739
CRP 1.133 1.028–1.249 0.012
Operation (non-anatomical) 1.473 0.863–2.515 0.156
Hepatectomy (minor) 0.922 0.367–2.315 0.863
Maximum tumor size 1.003 0.997–1.010 0.282
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5-68 months), and that in HCC with portal vein invasion
was 32 months (range, 3-82 months). The duration of
follow-up in HCC patients with malignant portal vein
invasion was shorter than that in HCC patients without
portal vein invasion because HCC patients died due to
tumor recurrence in the early period after surgery.
Risk factors for malignant portal vein invasion in HCC
patients
To identify risk factors for malignant portal vein inva-
sion in HCC, we performed a multivariate analysis on all
variables that were significantly associated with ma-
lignant portal vein invasion on univariate analysis. In-
creased serum ALP levels, increased maximum tumor
size, and intrahepatic metastasis were the predisposing
factors of malignant portal vein invasion by multivariate
analysis (Table 2).
Survival rate after surgery
For the HCC patients with malignant portal vein inva-
sion who underwent liver resection, the median disease-
free survival was 4.5 months and the overall survival was
25 months. The 1-year, 2-year, and 3-year disease-free
survival rates and overall survival rates in HCC patients
with malignant portal vein invasion were 30.6%, 26.1%,
and 21.2%, and 68.6%, 54.2%, and 41.6%, respectively,









Liver resection 0 (0%) 18 (4.4%) 0.091
Liver transplantation 3 (4.5%) 7 (1.7%) 0.154
RFA 6 (9.0%) 125 (30.5%) <0.001
TACE 39 (58.2%) 242 (59.0%) 0.894
Sorafenib 12 (17.9%) 67 (16.3%) 0.725
Radiation 9 (13.4%) 42 (10.2%) 0.400
Chemotherapy 5 (7.5%) 23 (5.6%) 0.573
RFA, Radiofrequency ablation; TACE, Transarterial chemoembolization.were 74.4%, 63.5%, and 58.5%, and 95.5%, 89.6%, and
85.1%, respectively (P <0.001 and P <0.001, respectively)
(Figure 1).
Recurrence after surgical resection
The incidence of tumor recurrence was 80.7% (67/83) in
HCC patients with malignant portal vein invasion and
38.8% (410/1056) in HCC without portal vein invasion.
The initial detection site was lung (50.7%) in HCC pa-
tients with malignant portal vein invasion and liverGrade (3 and 4) 0.627 0.311–1.267 0.194
Cirrhosis 1.426 0.879–2.314 0.150
Capsule formation 1.020 0.353–2.941 0.971
Capsular invasion 0.715 0.439–1.165 0.178
Bile duct invasion 0.752 0.302–1.873 0.540
Serosa involvement 5.863 1.372–25.058 0.017
Intrahepatic metastasis 1.787 1.098–2.910 0.020
Multicentric occurrence 0.048 0.00–195.191 0.474
Margin (mm) 1.006 0.986–1.026 0.566
AFP, Alpha-fetoprotein; ALP, Alkaline phosphate; ALT, Alanine
aminotransferase; AST, Aspartate aminotransferase; CRP, C-reactive protein;
GFR, Estimated glomerular filtration rate; GGT, Gamma-glutamyl transferase;
INR, International normalized ratio; PIVKA-II, Protein induced by vitamin
K antagonist-II.
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There was a difference in liver or lung as the initial de-
tection site of tumor recurrence between the two groups
(P <0.001 and P <0.001, respectively) (Table 3). However,
no significant difference was found in the recurrence in
bone, brain, and peritoneum between the two groups.
Radiofrequency ablation (RFA) in HCC patients without
portal vein invasion was used more often because of high
incidence of recurrence in liver, compared with HCC
patients with malignant portal vein invasion (P <0.001).
No HCC patients with portal vein invasion were treated
with liver resection due to recurrence. Liver transplant-
ation, TACE, sorafenib, radiation, and chemotherapy as
treatments for tumor recurrence were similar in both
groups (Table 4).
Prognostic factors for recurrence in HCC with malignant
portal vein invasion after surgery
Univariate analysis showed that increased AFP level, de-
creased serum albumin level, serosa involvement, and in-
trahepatic metastasis were closely associated with tumor
recurrence after liver resection (Table 5). On multivariate
analysis of the prognostic factors for disease-free survival
in HCC patients with malignant portal vein invasion, only
the CRP level (hazard ratio, 1.133; 95% confidence inter-
val, 1.028–1.249; P=0.012) was a significant independent
predictor of tumor recurrence after liver resection.
Discussion
The prognosis for patients who have HCC with malignant
portal vein invasion remained extremely poor in this
study, even though a few long-term survivors were ob-
served. Several studies have shown that tumor size, high
grade, the presence of fibrous capsule, and platelet counts
are strongly associated with portal vein invasion [8-10]. In
the present study, increased ALP levels, increased max-
imum tumor size, and intrahepatic metastasis were inde-
pendent predictors of malignant portal vein invasion in
HCC by multivariate logistic regression analysis. There-
fore, these factors may be helpful in predicting malignant
portal vein invasion before surgery for HCC.
Many studies reported that an increase in the serum
CRP level was associated with a shorter survival in pa-
tients with various malignancies, including multiple
myeloma [11], ovarian cancer [12], colorectal [13], and
esophageal cancer [14]. For the serum CRP levels associ-
ated with HCC, high CRP was linked to the diffuse type
of HCC and elevated preoperative CRP levels in patients
with HCC associated with tumor size and portal vein in-
vasion, and predicted recurrence after curative resection
and a poor surgical outcome [15,16].
The basis for the relationship between elevated CRP
and poor prognosis is unclear and there are several pos-
sible explanations. An elevated CRP level may reflect anon-specific inflammatory response to tumor necrosis
or local tissue damage, which may be indicative of a fa-
vorable environment for the establishment and growth
of tumor. The serum level of vascular endothelial growth
factor (VEGF), an angiogenic factor, is increased in the
presence of raised CRP concentration [17]. Angiogenesis
plays an important role in tumor growth and is associated
with a poor outcome [18]. This creates a microenvi-
ronment that favors tumor angiogenesis, proliferation,
growth, and metastases.
Tumor invasion in the remnant liver after surgery is
common in HCC patients with malignant portal vein inva-
sion [19]. However, our study revealed that lung metasta-
sis was common in HCC patients with malignant portal
vein invasion after surgery, while liver metastasis was
common in HCC patients without portal vein invasion.
Although intrahepatic recurrence predominates, prob-
ably because of the early spread of neoplasm and me-
tachronous multicentric carcinogenesis, several effective
therapeutic modalities can control recurrent disease (such
as repeated hepatectomy, TACE, percutaneous ethanol in-
jection therapy, microwave coagulation therapy, and RFA)
[16,20]. Compared with frequent intrahepatic recurrence,
the incidence of distant metastasis is relatively low in
HCC [21]. However, extrahepatic metastasis, such as lung,
was higher than intrahepatic metastasis in HCC with por-
tal vein invasion. The poor prognosis for patients with ex-
trahepatic metastasis of HCC occurs because it is an
indicator of an aggressive primary HCC [22].
Our study revealed that chest CT must be regularly
performed in HCC patients with malignant portal vein
invasion after surgical resection. In addition, patients
who had preoperatively elevated CRP levels, should be
closely monitored after hepatectomy because of a poor
prognostic factor of tumor recurrence.
Conclusion
In conclusion, our study reveals that increased ALP levels,
increased maximum tumor size, and intrahepatic metasta-
sis were independent predictors of malignant portal vein
invasion in HCC. CRP levels are closely associated with
the predisposing factor of tumor recurrence in HCC pa-
tients with malignant portal vein invasion after surgical re-
section, and lung metastasis is common.
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